Mitargos, a seed-stage biotech, is developing MG-001, an oral treatment that targets the root causes of brain damage by restoring mitochondrial bioenergetics. Focused on traumatic brain injury (TBI) and Alzheimer’s disease (AD), MG-001 aims to boost bioenergetics, enhancing mitochondria to support healing and resilience. Mitargos strives to transform health with a patient-centered, de-risked approach, offering hope to a field weighed down by setbacks and breaking the cycle of fear and hopelessness with fresh possibilities.
Company Details
- Employees
- 3
- Founded
- -
- Address
- San Diego, Ca 92101, Us
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- http://mitargos.com
- Keywords
- Neurodegeneration, Parkinson's, Alzheimer's, TBI.
- HQ
- SAN DIEGO, CA
Mitargos Questions
Mitargos's website is http://mitargos.com
Mitargos's LinkedIn profile is https://www.linkedin.com/company/mitargos
Mitargos has
3 employees.
View email and phone details for 3
employees at Mitargos.
Mitargos's industry is
Pharmaceutical Manufacturing
Mitargos's top competitors are
Ir Medtek,
Orlando Health Ventures,
Janina Goldberg Implementation Coaching & Consulting,
Qt Medical, Inc.,
Brightcore, Inc.,
Archemedic Solutions Llc,
Teal Health,
Impact Naturals,
Phronetik®,
Midr1v3.
Mitargos's categories are Pharmaceutical Manufacturing
Mitargos's founding year is 2023
